Vericel Overview
- Year Founded
-
1989
- Status
-
Public
- Employees
-
398
- Stock Symbol
-
VCEL
- Investments
-
2
- Share Price
-
$57.53
- (As of Friday Closing)
Vericel General Information
Description
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Contact Information
Website
www.vcel.comCorporate Office
- 25 Blue Sky Drive
- Burlington, MA 01803
- United States
Corporate Office
- 25 Blue Sky Drive
- Burlington, MA 01803
- United States
Vericel Stock Performance
As of 20-Nov-2026, Vericel’s stock price is $57.53. Its current market cap is $2.94B with 51M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $57.53 | $58.26 | $28.95 - $59.75 | $2.94B | 51M | 664K | $0.66 |
Vericel Financials Summary
As of 30-Sep-2026, Vericel has a trailing 12-month revenue of $324M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,985,628 | 1,783,797 | 2,705,999 | 1,679,194 |
| Revenue | 324,171 | 276,259 | 237,224 | 197,516 |
| EBITDA | 40,569 | 22,544 | 10,218 | (1,768) |
| Net Income | 33,308 | 16,518 | 10,362 | (3,182) |
| Total Assets | 517,110 | 487,969 | 432,722 | 353,657 |
| Total Debt | 90,689 | 96,369 | 98,966 | 88,043 |
Vericel Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vericel Comparisons
Industry
Financing
Details
Vericel Competitors (81)
One of Vericel’s 81 competitors is Athersys, a Formerly VC-backed company based in Cleveland, OH.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Athersys | Formerly VC-backed | Cleveland, OH | ||||
| Roche | Corporation | Basel, Switzerland | ||||
| Organogenesis Holdings | Pending Transaction (M&A) | Canton, MA | ||||
| AB Science | Formerly Accelerator/Incubator backed | Paris, France | ||||
| Lineage Cell Therapeutics | Corporation | Carlsbad, CA |
Vericel Patents
Vericel Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4486231-B1 | Devices for repairing cartilage defects | Active | 04-Mar-2022 | ||
| EP-4775181-A2 | Devices for repairing cartilage defects | Pending | 04-Mar-2022 | ||
| EP-4775181-A3 | Devices for repairing cartilage defects | Pending | 04-Mar-2022 | ||
| EP-4486231-A1 | Methods and devices for repairing cartilage defects | Active | 04-Mar-2022 | ||
| ES-3080984-T3 | Methods and devices for repairing cartilage defects | Active | 04-Mar-2022 | A61B90/06 |
Vericel Signals
Vericel Investments & Acquisitions (2)
Vericel’s most recent deal was a Merger/Acquisition with Sanofi (Cell Therapy and Regenerative Medicine Business) for . The deal was made on 30-May-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sanofi (Cell Therapy and Regenerative Medicine Business) | 30-May-2014 | Merger/Acquisition | Pharmaceuticals | ||
| RealBio Technology | 30-Sep-2009 | Early Stage VC | Discovery Tools (Healthcare) |
Vericel ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
30.81 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Vericel Exits (1)
Vericel’s most recent exit was on 30-Sep-2009 from RealBio Technology. The exit was categorized as with 4 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| RealBio Technology | 30-Sep-2009 | Completed |
|
Vericel Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Marrow Donation | Cambridge, MA | 2019 |
Vericel FAQs
-
When was Vericel founded?
Vericel was founded in 1989.
-
Where is Vericel headquartered?
Vericel is headquartered in Burlington, MA.
-
What is the size of Vericel?
Vericel has 398 total employees.
-
What industry is Vericel in?
Vericel’s primary industry is Biotechnology.
-
Is Vericel a private or public company?
Vericel is a Public company.
-
What is Vericel’s stock symbol?
The ticker symbol for Vericel is VCEL.
-
What is the current stock price of Vericel?
As of 20-Nov-2026 the stock price of Vericel is $57.53.
-
What is the current market cap of Vericel?
The current market capitalization of Vericel is $2.94B.
-
What is Vericel’s current revenue?
The trailing twelve month revenue for Vericel is $324M.
-
Who are Vericel’s competitors?
Athersys, Roche, Organogenesis Holdings, AB Science, and Lineage Cell Therapeutics are some of the 81 competitors of Vericel.
-
What is Vericel’s annual earnings per share (EPS)?
Vericel’s EPS for 12 months was $0.66.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process